Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

• Status: Active, not recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether 3 cycles of chemotherapy(CEV) are as effective as 6 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: Fudan University
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Vincristine

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study.

• Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.

• Received enucleation in the study eye.

• Monocular retinoblastoma.

Exclusion Criteria:

• Any previous disease in the study eye.

• Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).

• History of chemical intervention for retinoblastoma in the study eye.